ASRT
Assertio Holdings Inc

15,771
Mkt Cap
$81.75M
Volume
61,707.00
52W High
$15.15
52W Low
$7.71
PE Ratio
-2.70
ASRT Fundamentals
Price
$12.74
Prev Close
$11.62
Open
$11.69
50D MA
$10.95
Beta
1.31
Avg. Volume
51,781.20
EPS (Annual)
-$3.40
P/B
0.77
Rev/Employee
$2.15M
Loading...
Loading...
News
all
press releases
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.
Zacks·3d ago
News Placeholder
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.
Zacks·4d ago
News Placeholder
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
Zacks·5d ago
News Placeholder
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·5d ago
News Placeholder
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome
RARE resubmits FDA filing for UX111 after CRL, adding long-term neurologic and biomarker data, with a Q3 2026 decision in sight.
Zacks·6d ago
News Placeholder
Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 230.6% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·6d ago
News Placeholder
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
Zacks·9d ago
News Placeholder
Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and Assertio (ASRT) have performed compared to their sector so far this year.
Zacks·9d ago
News Placeholder
Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet
The consensus price target hints at a 249.9% upside potential for Assertio (ASRT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·23d ago
<
1
2
...
>

Latest ASRT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.